Uniting AI for Faster Healthcare Insights
Expanding Combined AI Platforms
The acquisition aims to combine the strengths of both companies. Realyze Intelligence's platform utilizes AI to match patients to clinical trials, expediting research and reducing costs. It examines structured and unstructured data in EHRs to identify ideal patients, while its clinician-trained AI can assemble suitable cohorts in seconds. Carta Healthcare's platform, on the other hand, applies AI to structured and unstructured data to reduce the time and price for data abstraction. Together, they anticipate that their combined technologies' "powerful" automation will offer faster insights and significantly reduce labor demands for various healthcare programs.For example, in oncology, cardiovascular health, and other specialty areas, the combined platforms have the potential to expand the feasibility of trials and research while increasing data abstraction with expert clinician oversight. This is a major step forward in leveraging AI to improve healthcare outcomes.
CEO Perspectives on the Importance of Data
Brent Dover, CEO of Carta Healthcare, emphasizes the significance of data in healthcare. He believes that data is the single most important ingredient for improving care practices and patient outcomes. From clinical trials to clinical registries, clinicians face vast amounts of data filled with valuable information. Realyze Intelligence's ability to use clinician-trained AI and a human-in-the-loop approach aligns with Carta Healthcare's mission to maximize insights from clinical data.This shared vision is driving the collaboration and innovation between the two companies. By combining their expertise, they are poised to make a significant impact on the healthcare industry.
Addressing Challenges in Clinical Trials
Aaron Brauser, founder and CEO of Realyze Intelligence, highlights the challenges faced by health systems and pharmaceutical companies in identifying and enrolling patients for clinical trials. The process is costly, labor-intensive, and time-consuming. However, with high-quality, timely data from EHRs and other systems, Realyze Intelligence aims to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways, and improve patient outcomes.For instance, by leveraging AI, they can quickly identify eligible patients and assemble suitable cohorts, saving valuable time and resources. This not only benefits the patients but also accelerates the progress of medical research.
Recent Developments and Funding
In 2023, Carta Healthcare closed a $25 million series B financing round, with additional investments from Memorial Hermann Health System and UnityPoint Health. This follows a $20 million Series B financing round in 2022, which included investors like Paramark Ventures, Frist Cressey Ventures, American College of Cardiology, Asset Management Ventures, CU Healthcare Innovation Fund, Mass General Brigham, Maverick Ventures Investment Fund, and Storm Ventures.In 2022, Carta Healthcare also became a certified software vendor for the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. This further showcases their commitment to advancing healthcare through technology.
Moreover, in April, researchers at Memorial Sloan Kettering Cancer Center applied machine learning and large language models to augment the manual curation of cancer data elements using the Realyze Intelligence platform. In February, Realyze Intelligence earned a position among the inaugural class of start-up companies selected for the CancerX Startup Accelerator, part of the Biden administration's Cancer Moonshot program.These recent achievements demonstrate the growing impact and potential of AI in healthcare and the importance of collaborations like the one between Carta Healthcare and Realyze Intelligence.